San Francisco, Feb. 11, 2016 -- Global Pharmacovigilance Market is expected to reach USD 5.51 billion by 2020. Increasing incidence rates of adverse drug reaction and the introduction of stringent drug safety regulations are some key drivers of this market. ADR is responsible for approximately 5% of the hospitalization in developed countries annually, and this is expected to boost usage rates over the next six years. Pharmacovigilance has witnessed a significant rise in usage rates in the recent times owing to growing global geriatric population triggering a growth in demand for new drug development. Additionally, health regulatory authorities such as the U.S. FDA and EMEA (European Medicines Agency) are now emphasizing on electronic submission of data which is also expected to drive the pharmacovigilance market.
Contract outsourcing pharmacovigilance market is expected to grow at a lucrative rate of over 13.1% during the forecast period. Service flexibility and cost effectiveness associated with outsourcing are some key factors accounting for the segment's lucrative growth.
Browse Full Research Report With TOC On "Pharmacovigilance Market Analysis By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial), By Type Of Service Providers (In House, Contract Outsourcing) And Segment Forecasts To 2020" at: http://www.radiantinsights.com/research/pharmacovigilance-market-analysis-by-clinical-trial-phases-preclinical-studies-phase-i-1-phase-ii-2-phase-iii-3-phase-iv-4-trial-by-type-of-service-providers-in-house-contract-outsourcing-and-segment-forecasts-to-2020
Further key findings from the study suggest:
- Pharmacovigilance services found the largest application in phase 4/IV clinical trial studies in 2013. Greater applicability and relevance are some factors accounting for the segment's market position.
- Contract outsourcing was the most revenue generating service provider segment in 2013. Minimization of upfront investments and reduction in fixed overhead costs are some factors expected to drive segment growth.
- North America was the largest regional market, accounting for over 40.0% of the revenue in 2013. Presence of stringent healthcare regulations implemented by the U.S. FDA and high market penetration rates of electronic medical records are some factors responsible for its large share.
- Asia Pacific is identified as the most lucrative market. Presence of a large pool of skilled labor and favorable business environments are some factors expected to drive regional market growth. Rapidly improving healthcare infrastructure in the emerging economies of India and China is also expected to provide new growth opportunities to the market participants.
- Key players of this market include Quintiles Transnational Corporation, PAREXEL International, Clinquest Group BV, Pharmaceutical Product Development, Accenture Plc., Boehringer Ingelheim GmbH and Cognizant Technology Solutions
- Providing customized end to end PV solutions & services and entering into strategic agreements are some key strategies adopted by these market players.
Browse All Reports of This Category at: www.radiantinsights.com/catalog/medical-devices
Global Pharmacovigilance Clinical Trial Phase Outlook (Revenue, USD Million, 2012 - 2020)
- Pre Clinical
- Phase 0
- Phase 1/I
- Phase 2/II
- Phase 3/III
- Phase 4/IV
Global Pharmacovigilance Service Provider Outlook (Revenue, USD Million, 2012 - 2020)
- In- House
- Contract Outsourcing
Pharmacovigilance Regional Outlook (Revenue, USD Million, 2012 - 2020)
- North America
- Europe
- Asia Pacific
- RoW
Related Reports by Radiant Insights:
- RFID Market –
http://www.radiantinsights.com/research/global-rfid-market-2014-2018
- Fiber Optic Sensor Market –
http://www.radiantinsights.com/research/global-fiber-optic-sensor-market-2014-2018
About Radiant Insights
Radiant Insights is a market research and consulting company offering syndicated research studies, customized reports, and consulting services. Our market research studies are designed to facilitate strategic decision making, on the basis of extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Using a patented and robust research methodology, we publish exhaustive research reports covering a host of industries such as Technology, Chemicals, Materials, and Energy.Radiant Insights has a strong base of analysts, consultants and domain experts, with global experience helping us deliver excellence in all research projects we undertake.
Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: [email protected]
Web: http://www.radiantinsights.com/


U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 



